Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas

F. H. Valone, David R Gandara, A. B. Deisseroth, E. A. Perez, A. Rayner, F. R. Aronson, J. Luce, C. Paradise

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The feasibility and efficacy of treating patients with locally recurrent or metastatic non-small cell lung cancer (NSCLC) or head/neck cancer with interleukin-2 (IL-2), cisplatin, and 5-fluorouracil (5-FU) was tested. Treatment was given every 28 days and consisted of cisplatin, 100 mg/m2 on days 1 and 8; 5-FU, 1,000 mg/m2 by continuous infusion on days 1-3; and IL-2, 12 million units/m2 by i.v. bolus on days 15-19. Thirty-four patients (22 NSCLC, 12 head/neck cancer) were registered in the study. The median age was 58 years; 59% had Karnofsky performance status of 70-80% and over one-half received prior therapy. All patients were evaluable for toxicity and 29 (18 NSCLC, 11 head/neck cancer) were evaluable for response. Twenty-five patients experienced at least one grade 3 or 4 toxicity, but these toxicities were transient and, in general, well tolerated. The response rate was 37% for NSCLC (0 complete response, 7 partial response) and 55% for head/neck cancer (2 complete response, 4 partial response). Two patients with head/neck cancer responded to treatment after failing prior therapy with cisplatin/5-FU alone. The combination of IL-2, cisplatin, and 5-FU is tolerable and active for treatment of NSCLC and head/neck carcinoma; the combination may not be cross-resistant with other chemotherapy combinations. Further studies of IL-2 combined with cisplatin/5-FU are warranted to determine the most effective dose and schedule.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalJournal of Immunotherapy
Volume10
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Interleukin-5
Head and Neck Neoplasms
Fluorouracil
Cisplatin
Interleukin-2
Neck
Head
Carcinoma
Lung
Non-Small Cell Lung Carcinoma
Therapeutics
Karnofsky Performance Status
Interleukin-12
Combination Drug Therapy
Appointments and Schedules

Keywords

  • 5-Fluorouracil
  • Cisplatin
  • Head/neck carcinoma
  • Interleukin-2
  • Non-small cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Valone, F. H., Gandara, D. R., Deisseroth, A. B., Perez, E. A., Rayner, A., Aronson, F. R., ... Paradise, C. (1991). Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. Journal of Immunotherapy, 10(3), 207-213.

Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. / Valone, F. H.; Gandara, David R; Deisseroth, A. B.; Perez, E. A.; Rayner, A.; Aronson, F. R.; Luce, J.; Paradise, C.

In: Journal of Immunotherapy, Vol. 10, No. 3, 1991, p. 207-213.

Research output: Contribution to journalArticle

Valone, FH, Gandara, DR, Deisseroth, AB, Perez, EA, Rayner, A, Aronson, FR, Luce, J & Paradise, C 1991, 'Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas', Journal of Immunotherapy, vol. 10, no. 3, pp. 207-213.
Valone, F. H. ; Gandara, David R ; Deisseroth, A. B. ; Perez, E. A. ; Rayner, A. ; Aronson, F. R. ; Luce, J. ; Paradise, C. / Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. In: Journal of Immunotherapy. 1991 ; Vol. 10, No. 3. pp. 207-213.
@article{196ffec59af240c882024de0b5dc1276,
title = "Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas",
abstract = "The feasibility and efficacy of treating patients with locally recurrent or metastatic non-small cell lung cancer (NSCLC) or head/neck cancer with interleukin-2 (IL-2), cisplatin, and 5-fluorouracil (5-FU) was tested. Treatment was given every 28 days and consisted of cisplatin, 100 mg/m2 on days 1 and 8; 5-FU, 1,000 mg/m2 by continuous infusion on days 1-3; and IL-2, 12 million units/m2 by i.v. bolus on days 15-19. Thirty-four patients (22 NSCLC, 12 head/neck cancer) were registered in the study. The median age was 58 years; 59{\%} had Karnofsky performance status of 70-80{\%} and over one-half received prior therapy. All patients were evaluable for toxicity and 29 (18 NSCLC, 11 head/neck cancer) were evaluable for response. Twenty-five patients experienced at least one grade 3 or 4 toxicity, but these toxicities were transient and, in general, well tolerated. The response rate was 37{\%} for NSCLC (0 complete response, 7 partial response) and 55{\%} for head/neck cancer (2 complete response, 4 partial response). Two patients with head/neck cancer responded to treatment after failing prior therapy with cisplatin/5-FU alone. The combination of IL-2, cisplatin, and 5-FU is tolerable and active for treatment of NSCLC and head/neck carcinoma; the combination may not be cross-resistant with other chemotherapy combinations. Further studies of IL-2 combined with cisplatin/5-FU are warranted to determine the most effective dose and schedule.",
keywords = "5-Fluorouracil, Cisplatin, Head/neck carcinoma, Interleukin-2, Non-small cell lung carcinoma",
author = "Valone, {F. H.} and Gandara, {David R} and Deisseroth, {A. B.} and Perez, {E. A.} and A. Rayner and Aronson, {F. R.} and J. Luce and C. Paradise",
year = "1991",
language = "English (US)",
volume = "10",
pages = "207--213",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas

AU - Valone, F. H.

AU - Gandara, David R

AU - Deisseroth, A. B.

AU - Perez, E. A.

AU - Rayner, A.

AU - Aronson, F. R.

AU - Luce, J.

AU - Paradise, C.

PY - 1991

Y1 - 1991

N2 - The feasibility and efficacy of treating patients with locally recurrent or metastatic non-small cell lung cancer (NSCLC) or head/neck cancer with interleukin-2 (IL-2), cisplatin, and 5-fluorouracil (5-FU) was tested. Treatment was given every 28 days and consisted of cisplatin, 100 mg/m2 on days 1 and 8; 5-FU, 1,000 mg/m2 by continuous infusion on days 1-3; and IL-2, 12 million units/m2 by i.v. bolus on days 15-19. Thirty-four patients (22 NSCLC, 12 head/neck cancer) were registered in the study. The median age was 58 years; 59% had Karnofsky performance status of 70-80% and over one-half received prior therapy. All patients were evaluable for toxicity and 29 (18 NSCLC, 11 head/neck cancer) were evaluable for response. Twenty-five patients experienced at least one grade 3 or 4 toxicity, but these toxicities were transient and, in general, well tolerated. The response rate was 37% for NSCLC (0 complete response, 7 partial response) and 55% for head/neck cancer (2 complete response, 4 partial response). Two patients with head/neck cancer responded to treatment after failing prior therapy with cisplatin/5-FU alone. The combination of IL-2, cisplatin, and 5-FU is tolerable and active for treatment of NSCLC and head/neck carcinoma; the combination may not be cross-resistant with other chemotherapy combinations. Further studies of IL-2 combined with cisplatin/5-FU are warranted to determine the most effective dose and schedule.

AB - The feasibility and efficacy of treating patients with locally recurrent or metastatic non-small cell lung cancer (NSCLC) or head/neck cancer with interleukin-2 (IL-2), cisplatin, and 5-fluorouracil (5-FU) was tested. Treatment was given every 28 days and consisted of cisplatin, 100 mg/m2 on days 1 and 8; 5-FU, 1,000 mg/m2 by continuous infusion on days 1-3; and IL-2, 12 million units/m2 by i.v. bolus on days 15-19. Thirty-four patients (22 NSCLC, 12 head/neck cancer) were registered in the study. The median age was 58 years; 59% had Karnofsky performance status of 70-80% and over one-half received prior therapy. All patients were evaluable for toxicity and 29 (18 NSCLC, 11 head/neck cancer) were evaluable for response. Twenty-five patients experienced at least one grade 3 or 4 toxicity, but these toxicities were transient and, in general, well tolerated. The response rate was 37% for NSCLC (0 complete response, 7 partial response) and 55% for head/neck cancer (2 complete response, 4 partial response). Two patients with head/neck cancer responded to treatment after failing prior therapy with cisplatin/5-FU alone. The combination of IL-2, cisplatin, and 5-FU is tolerable and active for treatment of NSCLC and head/neck carcinoma; the combination may not be cross-resistant with other chemotherapy combinations. Further studies of IL-2 combined with cisplatin/5-FU are warranted to determine the most effective dose and schedule.

KW - 5-Fluorouracil

KW - Cisplatin

KW - Head/neck carcinoma

KW - Interleukin-2

KW - Non-small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0025778523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025778523&partnerID=8YFLogxK

M3 - Article

C2 - 1651106

AN - SCOPUS:0025778523

VL - 10

SP - 207

EP - 213

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -